Neurocrine Biosciences Q3 Adj. EPS $3.29 Beats $1.91 Estimate, Sales $1.119B Beat $1.043B Estimate
Benzinga Newsdesk 5 hours ago
NewsEarningsEarnings Beats
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $3.29 per share which beat the analyst consensus estimate of $1.91 by 72.25 percent. This is a 51.61 percent increase over earnings of $2.17 per share
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $3.29 per share which beat the analyst consensus estimate of $1.91 by 72.25 percent. This is a 51.61 percent increase over earnings of $2.17 per share from the same period last year. The company reported quarterly sales of $1.119 billion which beat the analyst consensus estimate of $1.043 billion by 7.28 percent. This is a 40.77 percent increase over sales of $794.900 million the same period last year.